BACKGROUND: The prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter status for survival of patients with malignant gliomas remains controversial. Thus, the meta-analysis was performed in order to identify the impact of MGMT expression on prognosis of malignant gliomas. METHOD: An extensive literature search for relevant studies was conducted on PubMed, Embase, Web of Science, Cochrane Library, and CBM databases. Version 12.0 STATA software was used for the current meta-analysis. Hazard ratios (HRs) with their corresponding 95% confidence interval (95% CI) were also calculated to clarify the correlation between MGMT expression and the prognosis of malignant gliomas. RESULTS: Final analysis of 2,377 malignant gliomas patients from 32 clinical studies was performed. The meta-analysis results show that MGMT promoter group and unmethylated MGMT group has a significant difference (all P < 0.01). Combined HR of MGMT suggests that the methylated MGMT group has a longer overall survival than the unmethylated MGMT group (P < 0.01), but the Asians don't present a difference between the two groups. CONCLUSION: The meta-analysis study shows that the elevated MGMT promoter group may have a better prognosis in malignant gliomas patients, but the Asians don't have a better prognosis.
BACKGROUND: The prognostic significance of O6-methylguanine-DNA methyltransferase (MGMT) promoter status for survival of patients with malignant gliomas remains controversial. Thus, the meta-analysis was performed in order to identify the impact of MGMT expression on prognosis of malignant gliomas. METHOD: An extensive literature search for relevant studies was conducted on PubMed, Embase, Web of Science, Cochrane Library, and CBM databases. Version 12.0 STATA software was used for the current meta-analysis. Hazard ratios (HRs) with their corresponding 95% confidence interval (95% CI) were also calculated to clarify the correlation between MGMT expression and the prognosis of malignant gliomas. RESULTS: Final analysis of 2,377 malignant gliomaspatients from 32 clinical studies was performed. The meta-analysis results show that MGMT promoter group and unmethylated MGMT group has a significant difference (all P < 0.01). Combined HR of MGMT suggests that the methylated MGMT group has a longer overall survival than the unmethylated MGMT group (P < 0.01), but the Asians don't present a difference between the two groups. CONCLUSION: The meta-analysis study shows that the elevated MGMT promoter group may have a better prognosis in malignant gliomaspatients, but the Asians don't have a better prognosis.
Authors: Laia Capdevila; Sara Cros; Jose-Luis Ramirez; Carolina Sanz; Cristina Carrato; Margarita Romeo; Olatz Etxaniz; Cristina Hostalot; Ana Massuet; Jose Luis Cuadra; Salvador Villà; Carmen Balañà Journal: J Neurooncol Date: 2014-01-07 Impact factor: 4.130
Authors: Alba Fiorentino; Mario Balducci; Pasquale De Bonis; Silvia Chiesa; Laura De Filippo; Annunziato Mangiola; Fiorenza De Rose; Rosa Autorino; Carla Rinaldi; Sergio Fersino; Barbara Diletto; Paolo Matteucci; Elisa Ciurlia; Vincenzo Fusco; Carmelo Anile; Vincenzo Valentini Journal: Am J Clin Oncol Date: 2015-02 Impact factor: 2.339
Authors: A Tosoni; E Franceschi; M Ermani; R Bertorelle; L Bonaldi; V Blatt; Alba A Brandes Journal: J Neurooncol Date: 2008-04-23 Impact factor: 4.130